Smith & Nephew plc (SNN) Stock Price & Analysis
Smith & Nephew plc (SNN) closed at USD 30.88 on Thursday, October 22, 2026, up 5.64% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 29.23; the Oct 22, 2026 session ranged USD 29.6–30.88 on volume of 1,638,419 shares. Market capitalization is $12.92B, with a 52-week range of USD 26.12–37.09 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 10:38 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SNN.md
Key facts (SNN)
- 1 of 80 tracked superinvestors hold SNN (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Analysts: Hold (mean 2.67 on a 1–5 scale) (6 analysts), mean target USD 32.32 (range 29–38).
- Total return with dividends: 1Y -13.1% vs S&P 500 +14.9%; 5Y -0.9% vs S&P 500 +80.3%.
- Next earnings: 2026-08-04, EPS estimate USD 0.53, revenue estimate $1.56B.
Superinvestors (SEC 13F-HR, Q2 2026) (SNN)
1 of 80 tracked investors hold SNN. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Sarah Ketterer | Causeway Capital Management | 0.49% | $45.1M | Added +64.2% |
Analysts (SNN)
Consensus Hold (mean 2.67 on a 1–5 scale), 6 analysts; mean target USD 32.32 (low 29, high 38).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-31 | BTIG | Initiated | Neutral | |
| 2026-08-06 | JP Morgan | Downgrade | Overweight → Neutral | |
| 2026-08-05 | Barclays | Downgrade | Equal-Weight → Underweight |
Total return (dividends reinvested) (SNN)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -13.1% | -0.9% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -13.1% | -0.2% |
| Volatility (annualized) | 29.0% | 26.6% |
| Max drawdown | -27.1% (Nov 2025→Oct 2026) | -38.4% (Nov 2021→Sep 2022) |
Companies that name SNN in their SEC reports
| Relationship to SNN | Company | Filing | Sentence |
|---|---|---|---|
| partner | MATERIALISE NV (MTLS) | 20-F Apr 23, 2026 | “In the medical market, we have entered into collaborations with DePuy Synthes Companies of Johnson & Johnson, or DePuy Synthes, and Zimmer Biomet Holdings, Inc., or Zimmer Biomet, as well as with Encore Medical, L.P. (d/b/a Enovis), or Enovis, Limacorporate Spa, or Lima, Mathys AG, or Mathys (which is now part of the same company as Enovis), Smith & Nephew Inc., or Smith & Nephew, Corin Ltd, or Corin, Medtronic In…” |
SNN analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.53 | $0.00 | — | $1.56B | 1 |
| Next quarter (ends Dec 2026) | $0.71 | $0.00 | — | $1.81B | 1 |
| Current fiscal year (ends Dec 2026) | $2.22 | $2.05 | +8.5% | $6.47B | 4 |
| Next fiscal year (ends Dec 2027) | $2.41 | $2.28 | +5.5% | $6.80B | 4 |
Key Statistics (as of October 23, 2026 at 10:38 UTC)
| Price | USD 30.88 |
|---|---|
| Change | ▲ 5.64% (up) |
| Previous Close | USD 29.23 |
| Open | USD 29.61 |
| Day Range | USD 29.6 – 30.88 |
| 52-Week Range | USD 26.12 – 37.09 |
| Volume | 1,638,419 shares |
| Market Cap | $12.92B |
| Exchange | NYQ |
Technical Analysis (SNN)
Nexqual's technical model rates SNN "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 10:38 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 75.33 (overbought) |
| vs SMA50 | Above (USD 28.24) |
| MACD | 0.48 (positive) |
Analyst Ratings (SNN)
Wall Street analysts rate SNN "Hold" based on 6 analysts, with a mean price target of USD 32.32 (range USD 29–38), per Nexqual as of October 23, 2026 at 10:38 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 32.32 |
| High Target | USD 38 |
| Low Target | USD 29 |
| Buy / Hold / Sell | 1 / 5 / 0 |
Earnings (SNN)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD 0.53 |
| Revenue Estimate | $1.56B |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
Financials & Fundamentals (SNN)
| Total Revenue | $6.30B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +4.60% |
| Gross Margin | +68.44% |
| Operating Margin | +14.47% |
| Profit Margin | +10.08% |
| ROE | +11.85% |
| Debt / Equity | 0.73 |
| Current Ratio | 2.14 |
| Total Cash | $754.00M |
| Total Debt | $3.78B |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
Financial Health Score (SNN)
Nexqual rates Smith & Nephew plc's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 10:38 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 68%, operating 14% (last 12 months) |
| Balance Sheet | Strong — $754M cash vs $3.78B debt |
| Cash Flow | Solid — Operating cash flow $1.34B (TTM) |
| Efficiency | Mixed — ROE 12%, ROA 5.2% |
Ownership (SNN)
| Insider Ownership | +0.01% |
|---|---|
| Institutional Ownership | +11.45% |
| Shares Outstanding | 418.52M |
| Float | 2.11B |
| Short % of Float | +1.12% |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
Leadership (SNN)
Smith & Nephew plc is led by Deepak S. Nath, CEO & Director, per Nexqual as of October 23, 2026 at 10:38 UTC.
| CEO & Director | Deepak S. Nath |
|---|---|
| Interim CFO, Senior VP of Finance & Group Controller | Pierre Palassian |
| President of Global Operations | Paul Connolly |
| President Research & Development, ENT and Emerging Markets | Vasant Padmanabhan |
Major Backers & Investors (SNN)
Notable institutional backers of Smith & Nephew plc include River Road Asset Management, LLC, Goldman Sachs, Brandes Investment Partners L.P., according to Nexqual as of October 23, 2026 at 10:38 UTC.
Active Investors
| Investor | Stake |
|---|---|
| River Road Asset Management, LLC | 0.77% |
| Goldman Sachs | 0.73% |
| Brandes Investment Partners L.P. | 0.51% |
| LMR Partners LLP | 0.42% |
| Causeway Capital Management LLC | 0.37% |
| Wells Fargo & Company | 0.33% |
| Todd Asset Management LLC | 0.3% |
| Morgan Stanley | 0.29% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Dimensional Fund Advisors | 0.44% |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PEN | Penumbra, Inc. | USD 324.96 | ▲ 0.43% |
| GMED | Globus Medical, Inc. | USD 81.66 | ▲ 3.79% |
| GKOS | Glaukos Corporation | USD 176.69 | ▼ 0.09% |
| PODD | Insulet Corporation | USD 148.12 | ▲ 4.38% |
| BIO | Bio-Rad Laboratories, Inc. | USD 363.5 | ▲ 0.83% |
| TXG | 10x Genomics, Inc. | USD 69.75 | ▼ 7.73% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:38 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt